Abstract The case report is a description of a single case of hepatic myelolipoma, a very rare benign hepatic tumor, evaluated with contrast sonography, in a 72-year-old female. It was previously reported as hyperechoic lesions at sonography. CEUS features of the lesion were: homogeneous hyperenhancement in the arterial phase and a slight hyperenhancement in the portal venous phase typical of benign tumors. The case report shows CEUS may help in differential diagnosis between benign and malignant lesions, but only the biopsy of the tumor and the pathological evaluation allows the diagnosis.
Introduction
Myelolipoma is a benign tumor composed of fat and bone marrow components. It is more frequently located in the adrenal cortex [1] . Indeed, myelolipoma of the liver is a very rare tumor; only a few cases are reported in the literature and they are individual case reports [2] [3] [4] .
Case history
We report the case of an otherwise healthy 72-year-old female who has been evaluated for 3 years in another institution before coming at our evaluation for the follow up of a focal liver lesion incidentally identified. The patient had no symptoms related to the tumor.
Indeed, the patient initially underwent a gray-scale abdominal sonography for dyspepsia and a small hyperechoic tumor was detected in the right liver lobe.
The computed tomography confirmed a 20-mm-diameter tumor of the right liver lobe. The tumor resulted hypodense after administration of intravenous contrast (Fig. 1 ). After about 2 years, the computed tomography showed an increase of the diameter of the tumor from 20 to 30 mm (Fig. 2) . The patient was then also investigated with a magnetic resonance; the fat saturation imaging, with suppression of the signal from adipose tissue, confirmed the tumor of the right lobe of the liver with an abundant fatty component (Fig. 3) .
After 6 months, the patient was evaluated at our department and the tumor showed a further increase in diameter. Indeed, the gray-scale sonography confirmed a single hyperechoic focal lesion in the right lobe of the liver, (Fig. 4) . The color sonography of the tumor revealed the presence of intranodular vessels (Fig. 5) .
On contrast-enhanced ultrasound (CEUS), after the injection of 2.4 ml contrast medium (SonoVue Ò , Bracco, Milan, Italy), the tumor resulted homogeneously hyperenhanced in the arterial phase (Fig. 6a) and slightly hyperechoic in the portal venous phase in comparison with the surrounding parenchyma (Fig. 6b) .
Since the tumor had demonstrated an increase in diameter, the patient underwent a sonographically guided biopsy. An automated 21 gauge device was used for the biopsy.
Microscopically, the tumor was composed of adipose tissue and hematopoietic elements containing erythroid, megakaryocytes and myeloid colonies, allowing the diagnosis of myelolipoma (Fig. 7) .
A Philips iU22 ultrasound machine (Philips Healthcare, Best, The Netherlands) with a 2-to 5-MHz convex probe and with a contrast harmonic imaging technology was used for our sonographic examinations.
The patient gave informed written consent for all imaging examinations and for the biopsy.
Conclusions
Myelolipoma of the liver is a very rare benign tumor. It was previously reported as hyperechoic lesions at sonography [2, 3] . This is the first case reporting the CEUS features of hepatic myelolipoma in the literature. CEUS features, namely a homogeneous hyperenhancement in the arterial phase and a slight hyperenhancement in the portal venous phase, are typical of benign tumors. Focal nodular hyperplasia and high-flow hemangiomas may show this pattern of enhancement [5] . Therefore, the CEUS features of hepatic myelolipoma in this single case resulted attributable to a benign nodule and it should be considered in the differential diagnosis with other benign tumors. Only the biopsy of the tumor and the pathological evaluation allowed the diagnosis. Informed consent All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. All patients provided written informed consent to enrollment in the study and to the inclusion in this article of information that could potentially lead to their identification.
Ethical standard The study was conducted in accordance with all institutional and national guidelines for the care and use of laboratory animals. Fig. 7 Pathologic examination of the biopsy. Hematoxylin-eosin stain. Magnification 920. Erythroid, megakaryocytes and myeloid colonies are identifiable among fat cells
